NKTX
NASDAQ
$2.57
Nkarta Inc (NKTX)
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and markets cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California.
Sector:
Healthcare
Industry:
Biotechnology
Strong Buy
Target: $11.33 (+340.86%)
Market Cap
$198M
P/B Ratio
0.66
Free Cash Flow Yield
-44.76%
Beta (5Y)
1.29
Price Chart
Valuation
Market Cap$198M
P/S1000000.00
P/B0.66
Profitability
Total Revenue (TTM)-$1.54M
Gross Profit (TTM)-$36M
EBITDA-$107M
EPS-$1.41
Financial Health
Free Cash Flow Yield-44.76%
Growth & Risk
FCF 5Y CAGR+9.52%
Beta (5Y)1.29
Sharpe Ratio0.65